

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM392529

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
IPD ANALYTICS, LLC		06/29/2016	Limited Liability Company: FLORIDA
IPD CAPITAL, LLC		06/29/2016	Limited Liability Company: FLORIDA
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	BANKUNITED, N.A.		
<b>Street Address:</b>	7815 NW 148th STREET		
<b>City:</b>	MIAMI LAKES		
<b>State/Country:</b>	FLORIDA		
<b>Postal Code:</b>	33016		
<b>Entity Type:</b>	National Association: FLORIDA		
<b>PROPERTY NUMBERS Total: 2</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	4267157	IPDANALYTICS	
<b>Registration Number:</b>	4800357	IPD ANALYTICS	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	7346231625		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	734-623-1906		
<b>Email:</b>	cmitchell@dickinsonwright.com		
<b>Correspondent Name:</b>	CHRISTOPHER A. MITCHELL		
<b>Address Line 1:</b>	350 S. Main St.		
<b>Address Line 2:</b>	Suite 300		
<b>Address Line 4:</b>	Ann Arbor, MICHIGAN 48104		
<b>ATTORNEY DOCKET NUMBER:</b>	61180-4		
<b>NAME OF SUBMITTER:</b>	Christopher A. Mitchell		
<b>SIGNATURE:</b>	/Christopher A. Mitchell/		
<b>DATE SIGNED:</b>	07/25/2016		
<b>Total Attachments: 7</b>			

OP \$65.00 4267157

source=IPD Security Agreement#page1.tif  
source=IPD Security Agreement#page2.tif  
source=IPD Security Agreement#page3.tif  
source=IPD Security Agreement#page4.tif  
source=IPD Security Agreement#page5.tif  
source=IPD Security Agreement#page6.tif  
source=IPD Security Agreement#page7.tif

## CONFIRMATORY SECURITY AGREEMENT

THIS AGREEMENT (this "Agreement") is entered into as of June 29, 2016, by and among IPD ANALYTICS, LLC, a Florida limited liability company ("IPDA", "Borrower" and a "Grantor"), IPD CAPITAL, LLC, a Florida limited liability company ("IPDC", "Borrower" and a "Grantor" and, collectively with IPDA, the "Borrowers" and the "Grantors") and BANKUNITED, N.A., a national association (the "Secured Party").

### Recitals

A. The Grantors and the Secured Party entered into that certain Credit Agreement, dated June 29, 2016 (as amended, supplemented, restated or otherwise modified from time to time), pursuant to which the Secured Party has made available to the Borrowers loans and other financial accommodations as set forth in the Credit Agreement.

B. In connection with the Credit Agreement, the Grantors and the Secured Party entered into that certain Security Agreement dated June 29, 2016 (as amended, supplemented, restated or otherwise modified from time to time), pursuant to which a first-priority security interest in the Collateral (as defined in the Security Agreement and the Credit Agreement) was assigned and granted to the Secured Party as security for the Obligations (as defined in the Security Agreement and the Credit Agreement).

C. Pursuant to the terms of the Security Agreement, the Grantors transferred, assigned and granted to the Secured Party a first-priority security interest (subject to Permitted Liens (as defined in the Security Agreement and the Credit Agreement)) in substantially all of the assets of the Grantors, including all right, title and interest in, to and under all existing or hereafter acquired or arising Intellectual Property (as defined in the Security Agreement), to secure the prompt and complete payment and performance of the Obligations.

### Agreement

In consideration of the recitals set forth above and the mutual agreements contained herein and in the Credit Agreement, the Security Agreement, and the other Loan Documents, the Grantors hereby grant to the Secured Party, to secure the Obligations, a continuing security interest in all of the Grantors' right, title and interest in, to and under the Intellectual Property, including without limitation the following:


- (1) Each trademark registration referred to in Exhibit A, attached hereto, and the subject trademark thereof, together with the goodwill associated therewith;
- (2) Each copyright referred to in Exhibit A, attached hereto, including the associated copyright registrations and copyright applications.

The security interest granted to the Secured Party herein is granted in furtherance, and not in limitation of, the security interests granted to the Secured Party pursuant to the Security Agreement. The Grantors acknowledge and affirm that the rights and remedies of the Secured Party with respect to the security interest in the Intellectual Property made and granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the Security Agreement, the terms of the Security Agreement shall govern. All capitalized terms used but not defined herein shall have the respective meanings ascribed thereto in the Security Agreement and the Credit Agreement.


[CONTINUED ON FOLLOWING PAGE]

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their officers thereunto duly authorized as of the day and year first above written.


IPD ANALYTICS, LLC

By:   
Name: Howard B. Kass  
Title: President

IPD CAPITAL, LLC

By:   
Name: Howard B. Kass  
Title: President

BANKUNITED, N.A.

By:   
Name: Vanessa C. Civalero  
Title: Senior Vice President

**Exhibit A**

No.	Full Title	Copyright Reg. Number	Reg. Date
1	Zerenex Update (KERX): An Early Look At The Zerenex Patent Portfolio.	TX0007672859	2/5/2013
2	Align (ALGN) v. ClearCorrect: Approaching Trials Threaten ClearCorrect's Products.	TX0007672964	2/5/2013
3	Myriad (MYGN): Supreme Court To Consider Validity of Myriad Patents Covering Isolated DNA.	TX0007720751	4/5/2013
4	Lialda (SHPG v. ACT): A Preview Of The Coming Trial.	TX0007720755	4/3/2013
5	Cubicin (CBST v. HSP): Cubist Appears To Have Advantage Heading Into Markman Hearing.	TX0007720758	4/5/2013
6	AndroGel (ABBV): Supreme Court To Consider Whether Reverse-Payment Agreements Violate Anti-Trust Laws.	TX0007720753	4/5/2013
7	Enzo (ENZ): An Early Look At Enzo's Recent Patent Lawsuits.	TX0007777035	8/2/2013
8	Juxtapid (AEGR): Dosing Patent Likely To Protect Juxtapid From Generic Competition Until 2027.	TX0007777006	8/2/2013
9	Zytiga (JNJ, BTG): An Overview Of The Zytiga Patent Situation.	TX0007776998	8/2/2013
10	Xifaxan (SLXP): An Overview Of Salix's Patent Portfolio For Xifaxan 550 mg And 200 mg.	TX0007777003	8/2/2013
11	Drisapersen (Prosenza) And Eteplirsen (Sarepta): An Overview Of The Patent Situation.	TX0007777010	8/2/2013
12	Amitiza (SCMP): An Early Look At The Patent Litigation.	TX0007777032	8/2/2013
13	Effient (LLY): An Overview Of Eli Lilly's Patent Portfolio For Effient.	TX0007824332	11/25/2013
14	Suboxone Film (Reckitt Benckiser): An Early Look At The Patent Litigation.	TX0007824326	11/25/2013
15	Gilenya (NVS): An Overview Of Novartis's Patent Portfolio.	TX0007824331	11/25/2013
16	Sequenom, Verinata, Ariosa, & Natera: An Overview Of The Patent Landscape And Upcoming Markman Hearings.	TX0007824323	11/25/2013
17	Ampyra (ACOR): An Overview Of Acorda's Patent Protection For Ampyra.	TX0007824324	11/25/2013
18	Competitive Landscape Analysis: PCSK9 Antibodies.	TX0007824329	11/25/2013
19	Angiomax (MDCO): A Preview Of The Coming Trial		

	Against Hospira.	TX0007824321	11/25/2013
20	OxyContin (Purdue): A Preview Of The Coming Trial.	TX0007824325	11/25/2013
21	Truvada & Atripla (GILD v. TEVA): Heading Into Trial, Gilead Appears To Have Advantage.	TX0007824328	11/25/2013
22	Prezista (JNJ): Prezista May Face Generic Competition in 2019		
23	Hetlioz (VNDA): An Overview Of Vanda's Patent Portfolio.	TX0007846279	12/23/2013
24	Velcade (Millennium): Velcade Unlikely To Face Generic Competition Before 2022.	TX0007846276	1/7/2014
25	Edwards & Medtronic (EW, MDT): Tavi Patent Landscape.	TX0007846167	1/7/2014
26	InterDigital (IDCC) v. Nokia, Huawei, and ZTE: InterDigital Likely to Suffer Strategic Loss at ITC.	TX0007846290	1/7/2014
27	Gemalto (GTO) v. Samsung, HTC, Google (GOOG): Appeals Court Appears inclined to Affirm Gemalto Loss	TX0007947703	2014-08-06
28	Vinetx v. Apple (VHC AAPL): Federal Circuit Likely Will Affirm Infringement And Validity Verdicts That Favor VinetX But Lawsuit For new Trial on Damages	TX0007947704	2014-08-06
29	Apple v. Motorola Mobility (AAPL v. GOOG): Appeals Court to Consider Whether To Revive Apple's <sup>TM</sup> s Request for Court-Determined FRAND Rate	TX0007947706	2014-08-06
30	Apple v. Motorola Mobility (AAPL v. GOOG, MSI) : Appeals Court Likely Will Give Parties Another Chance for Remedies	TX0007947708	2014-08-06
31	Oracle (ORCL) v. Google (GOOG): Appeals Court Likely to Issue Decision That Favors Oracle	TX0007947710	2014-08-06
32	Apple V. Motorola ( AAPL V. GOOG, MSI): Appeals Court Likely Will Give Parties Another Chance for Remedies	TX0007947719	2014-08-06
33	ResMed v. Apex and BMC: An Early Look at the Patent Disputes	TX0007947722	2014-08-06
34	Proair HFA ( TEVA v. PRGO): Perrigo May Launch Generic As Early as 2017	TX0007947724	2014-08-06
35	Xeljanz ( PFE): Pfizer's Xeljanz Likely Protected From Generic Competition Until 2025	TX0007947726	2014-08-06
36	Gralise ( DEPO): Heading Into Trial, Depomed Appears To Have Advantage	TX0007947757	2014-08-06
37	Exelon Patch ( NVS): Novartis v. Par Trial Begins Tomorrow	TX0007947758	2014-08-06
38	Xtandi ( MDVN): Medivation's Xtandi Likely Protected From Generic Competition until 2027	TX0007947759	2014-08-06
39	Lidoderm ( EDNP): Heading Into Trial, Twi Appears To Have Advantage	TX0007947761	2014-08-06
40	Adamas Pharmaceuticals ( ADMS): An Overview Of The Patent Situations For Namenda XR, MDX-8704, And ADS-5102	TX0007947762	2014-08-06
41	Xarelto ( JNJ, BAY): Janssen's Xarelto Likely Protected From Generic Competition until 2024	TX0007947763	2014-08-06
42	Aubagio ( Sny): Genzyme's Aubagio Likely Protected From Generic Competition Until 2026	TX0007947764	2014-08-06
43	Restasis (AGN): A Close Look at Allergan's Patent Protection For Restasis	TX0007947765	2014-08-06
44	Astrazeneca's Brilinta Likely Protected From Generic Competition Until 2024	TX0007947766	2014-08-06

45	Cubicin ( CBST v. HSP): Heading Into Trial, Cubist Has Advantage On 2019 and 2020 Patents	TX0007947767	2014-08-06
46	Pradaxa ( Boehringer Ingelheim): An Overview Of The Patent Portfolio For Pradaxa	TX0007947769	2014-08-06
47	Lantus and LY2963016 ( SNY, LLY): An Early Look At the Patent Lawsuit	TX0007947770	2014-08-06
48	InterDigital (IDCC) v. Samsung, Nokia, and ZTE: InterDigital Likely To Suffer Strategic Loss AT ITC	TX0007948102	2014-08-06
49	Mentor v. Synopsys (MENT, SNPS): Mentor v. Synopsys: Mentor Has Narrow Overall Advantage Against Synopsys	TX0007948116	2014-08-06
50	Akamai v. Limelight: Limelight Has the Advantage Persuading The Supreme Court That it Does Not Infringe Akamai's Patent	TX0007948122	2014-08-06
51	Broadcasters v. Aereo: Supreme Court Likely to be Skeptical of Aereo: Decision May Create Risk for Cloud Services	TX0007948124	2014-08-06
52	An Overview of Nokia's Patent Monetization Posture	TX0007948135	2014-08-06
53	Intel v. Nvidia ( NVDA): Nvidia Unlikely to Obtain Further Patent Payments From Intel after January 2016	TX0007948138	2014-08-06
54	Vringo v. Google: Vringo Has Advantage Using Appeal to Increase Damage Award	TX0007948140	2014-08-06
55	Illumina And Sequenom: Parties Grapple for Advantage	TX0007948145	2014-08-06
56	Revlimid ( Lenalidomide ) Global Insights Report : European Oppositions Threaten Revlimid Patents; Provide insight into US Challenges	TX0007948150	2014-08-06
57	Competitive Landscape Analysis : Diabetes Care Devices	TX0007948152	2014-08-06
58	Multaq (SNY): An Early Look At The Patent Litigation	TX0007947993	2014-08-07
59	Otrexup ( ATRS): An Overview Of Antares' Attempt To Block medac's Launch Of Rasuvo	TX0007947995	2014-08-07
60	Subsys ( INSY): Insys's Subsys Likely Protected From Generic Competition Until 2027	TX0007948000	2014-08-07
61	Hyperion Therapeutics (HPTX): An Overview Of The Patent Situations For Ravicti, Buphenyl, And DiaPep277	TX0007948012	2014-08-07
62	OxyContin(Purdue): A Preview Of The Coming Trial	TX0007948014	2014-08-07
63	Competitive Landscape Analysis : Achillion (ACHN) HVC Pipeline	TX0007948017	2014-08-07
64	Angiomax (MDCO): A Preview Of The Coming Trial Against Mylan	TX0007948018	2014-08-07
65	Savella (ACT): An Early Look At The Patent Litigation	TX0007948019	2014-08-07
66	Competitive Landscape Analysis (PD-1 & PD-L1 Antibodies): BMS Patents May Cover Three Competing PD-1 Products	TX0007948020	2014-08-07
67	Sunovion's Latuda Likely Protected From Generic Competition Until At Least 2018	TX0007948029	2014-08-07
68	Masimo (MASI) v. Phillips Update: Battle On Pulse Oximetry Patents Heads To First Trial In Mid-September	TX0007952880	2014-08-27
69	Xifaxan (SLXP): An Updated Overview Of Salix's Patent Protection For Xifaxan 550mg and 200mg	TX0007953030	2014-08-27
70	Fanapt : An Early Look At The Patent Litigation	TX0007953036	2014-08-27
71	Biodelivery Sciences Int'l (BDSI): An Overview Of The Patent Situations For Its Products	TX0007987553	2014-10-29
72	Mobileye Patents May Not Deter Competitors	TX0007987557	2014-10-29
73	Treanda (TEVA): An Early Look At The Patent	TX0007987550	2014-10-29

	Litigation		
74	Interdigital (IDCC) v. Nokia And ZTE: Interdigital At Disadvantage Reversing Adverse ITC Decision On Appeal	TX0008018435	2015-01-07
75	Supreme Court Likely to Require Deference To Trial Court Decisions Interpreting Patents	TX0008018448	2015-01-07
76	Vimpat (UCB): An Early Look At The Patent Litigation	TX0008018459	2015-01-07
77	Remodulin (LITHR): A Look At Second Wave Lawsuits	TX0008018450	2015-01-07
78	Nvidia v Samsung and Qualcomm: An Early Look At The ITC Lawsuit	TX0008018453	2015-01-07
79	Raptor ( RPTP): A Look At The Procysbi Patent Situation	TX0008018458	2015-01-07
80	JNJ V. BSX: An overview of Upcoming Trial In Guidant Merger Breach of Contract Dispute	TX0008018440	2015-01-07
81	Cisco (CSCO) v. Arista (ANET): Lawsuits May Materially Threaten Arista	TX0008018433	2015-01-07
82	Revlimid (Celg): Natco Discloses Its Polymorph; Generic Competition Expected In 2019 Or 2023 (March 2, 2015)	TX0008114783	2015-09-24
83	Humira (Adalimumab): An Analysis Of Abbvie'S New Formulation Patents (July 14, 2015)	TX0008169138	2015-09-25
84	Humira (Adalimumab) Global Insights Report: Abbvie Submits Response In European 2022 Dosing Patent Opposition (January 9, 2015)	TX0008110949	2015-08-14
85	Zytiga (Abiraterone): Understanding Janssen'S And Prospective AndA Filers' Abiraterone Patents (March 16, 2015)	TX0008114795	2015-09-24
86	Samsung V. Nvidia: Samsung Lawsuits Present Credible Counterthreat To Nvidia (May 12, 2015)	TX0008169126	2015-09-25
87	Dallresp: An Early Look At The Litigation (July 20, 2015)	TX0008169142	2015-09-25
88	Impax'S Rytary Likely Protected From Generic Competition Until At Least 2018 (August 3, 2015)	TX0008169325	2015-09-25
89	Align (Align): Align'S Patent Portfolio Appears Unlikely To Deter Competitors After October 2017 (June 30, 2015)	TX0008169140	2015-09-25
90	Placental Tissue Grafts (Mdxg): Validity Of Mdxg Patents Appears Vulnerable (March 20, 2015)	TX0008114936	2015-09-24
91	Nevro (Nvro): Nevro Patent Faces Significant Threat From Bsx Ipr Petitions (July 8, 2015)	TX0008169134	2015-09-25
92	Sirona Dental (Siro): An Early Look At The Petitions For Ipr Proceedings (May 19, 2015)	TX0008169332	2015-09-25
93	Alimta (Lly): Heading Into Upcoming Infringement Trial, Lilly Appears To Have Advantage On 2022 Patent (May 20, 2015)	TX0008169303	2015-09-25
94	Copaxone 40 Mg/Ml (Teva): An Early Look At The Petitions For Ipr Proceedings (March 4, 2015)	TX0008114789	2015-09-24
95	Inomax (Mnk): An Early Look At The Petitions Requesting Ipr Proceedings (April 8, 2015)	TX0008114913	2015-09-24



96	Oxtellar Xr And Trokendi Xr (Supn): A Look At Two Sets Of Supernus Patents (April 23, 2015)	TX0008114946	2015-09-24
97	Trecanda (Teva): Heading Into Markman Hearing, Teva Appears To Have Advantage (April 20, 2015)	TX0008114906	2015-09-24
98	Xifaxan (Vrx): An Updated Overview Of The Patent Portfolio For Xifaxan 550 Mg And 200 Mg (July 29, 2015)	TX0008169147	2015-09-25
99	Carnegie Mellon University V. Marvell: Federal Circuit Likely Will Overturn Damage Award (April 2, 2015)	TX0008114922	2015-09-24
100	An Overview Of Depomed'S Patent Infringement Lawsuits Against Purdue And Endo (July 7, 2015)	TX0008169136	2015-09-25
101	Nucynta & Nucynta Er (Depo): An Overview Of The Patent Litigation (June 8, 2015)	TX0008169145	2015-09-25

No.	Full Title	Trademark Reg. Number	Reg. Date
1.	IPDANALYTICS (+Design)	4267157	2013-01-01
2.	IPDANALYTICS (+Design)	4800357	2015-08-25